INCA033989
Monoclonal antibody
Evidence outlook · registrational
Essential Thrombocythemia: registrational readout pending
No completed mid-stage readout is on record. Registrational readout expected around 2029-06-15.
How the evidence outlook works ↗
Featured trials
The studies most instrumental to this drug's clinical progression, individually graded on design and result. The complete registry, including every study not featured here, is listed below.
| Trial | Phase | Endpoint | Key result | Signal | Source |
|---|---|---|---|---|---|
NCT05936359 NCT05936359 · Myeloproliferative Neoplasms Registry: NCT05936359 | 1 | Number of participants with Dose Limiting Toxicities (DLTs) (Up to 28 days); Number of participants with Treatment-emergent Adverse Events (TEAEs) (Up to 3 years and 60 days); Number of participants with TEAEs leading to dose modification or discontinuation (Up to 3 years and 60 days) 2028-02-29 | In progress: results expected 29 Feb 2028 | not yet graded | link ↗ |
View 1 more trial
EXCALIBUR-ET2 NCT07623200 · Essential Thrombocythemia Registry: NCT07623200 | 3 | Durable clinicohematologic response (DCR) (Week 24) 2029-06-15 | In progress: results expected 15 Jun 2029 | not yet graded | link ↗ |
All registered studies
Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase.
Phase 3 (1)
What this study did
Phase 1 (3)
What this study did
What this study did
What this study did
Competitive landscape
This drug's own stage for Essential Thrombocythemia: Phase 3. Competitors below are sorted furthest-along first.
| Drug | Stage | Modality | Mechanism | Evidence signal | Reported efficacygraded featured trials | |
|---|---|---|---|---|---|---|
| INCA033989: this drug | Phase 3 | Monoclonal antibody | mutant calreticulin (mutCALR) | not yet graded | No reviewed efficacy summary in this indication | |
| Ropeginterferon Alfa-2b (Besremi) | Approved | Protein / enzyme therapeutic | Type I interferon receptor | Partial signal | NCT04285086: Durable modified ELN response at months 9 and 12: 39 (43%) of 91 ropeginterferon alfa-2b vs five (6%) of 83 anagrelide | |
| Bomedemstat | Phase 3 | Small molecule | LSD1 (lysine-specific demethylase 1) | not yet graded | No reviewed efficacy summary in this indication |
Upcoming events
(3 total)
Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.
Follow INCA033989 to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.
Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.